Advancing Bone Health: European Commission Approves Biocon Biologics' Denosumab Biosimilars

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Biocon-Biologics

More Like This

PR Newswire associated0

Bone Health: Biocon Biologics Receives Positive CHMP Opinions for Biosimilar Denosumab in Europe

PR Newswire associated0

mAbxience Announces European Commission Approval of Denosumab Biosimilars

Samsung Bioepis Gains European Commission (EC) Approval for Denosumab Biosimilar (OBODENCE™, XBRYK™)

Celltrion Expands Biosimilar Portfolio in the European Union Following European Commission Approval of Two Biosimilars

European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14

Celltrion Receives Positive CHMP Opinion for Three Biosimilars in the European Union

PR Newswire associated0

Accord Healthcare Receives Positive CHMP Opinion for Denosumab, Osvyrti®, and Jubereq®

Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints